BPC-157 vs TB-500: Comparing Two Tissue-Repair Peptides Studied in Research
BPC-157 and TB-500 (a synthetic fragment of Thymosin Beta-4) are the two peptides most frequently compared in tissue-repair research. This article walks through their structural differences, distinct mechanisms of action in animal models, and why researchers sometimes study them in parallel.
For in-vitro and laboratory research only. PrimeHelix Labz does not provide guidance on human use of any compound discussed below.
BPC-157 and TB-500 are the two peptides most frequently mentioned in the same breath in tissue-repair research forums and review papers. They are often confused, partly because both have shown effects in wound-healing animal models and partly because they are sometimes used in parallel in preclinical studies. They are, however, structurally and mechanistically very different molecules. This article walks through the differences.
What each molecule actually is
BPC-157
BPC-157 is a synthetic 15–amino-acid pentadecapeptide. It is a partial sequence of a larger protective protein originally isolated from human gastric juice. It does not exist as a free molecule in nature in this form—it is an engineered fragment selected for its activity in injury models. For a deeper overview of BPC-157, see our BPC-157 research guide.
TB-500
“TB-500” is the research-supply name for a synthetic 17–amino-acid fragment (residues 17–23 of the parent sequence, plus modifications, depending on supplier) of Thymosin Beta-4 (Tβ4). Tβ4 itself is a naturally occurring 43–amino-acid protein found in nearly all human cells; it is one of the most abundant intracellular actin-sequestering proteins in mammals.
It is important to note that TB-500 is not biologically identical to full-length Tβ4. It contains the active actin-binding sequence but lacks much of the surrounding structure. Some published studies use full Tβ4; many supply catalogs sell only the truncated TB-500 fragment. Reading the COA carefully is therefore important.
Side-by-side comparison
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Origin | Synthetic fragment of a gastric-juice protective protein | Synthetic fragment of Thymosin Beta-4 (Tβ4) |
| Length | 15 amino acids | ~17 amino acids (sequence varies by supplier) |
| Approx. molecular weight | ~1419.5 Da | ~1900 Da |
| Primary mechanisms studied | VEGFR2 / angiogenic signaling, NO pathway, growth-factor receptor expression | Actin sequestration, cell migration, anti-inflammatory pathways |
| Common research models | Tendon and ligament repair, gastric ulcer, IBD models | Cardiac repair, dermal wound, corneal injury |
| Stability (lyophilized, −20°C) | ~24–36 months | ~24–36 months |
Mechanism of action: the core difference
BPC-157 has been studied primarily for its angiogenic and growth-factor-modulating effects—in other words, the published rodent literature reports increased blood-vessel formation and altered expression of growth-factor receptors at injury sites.
TB-500 (and its parent Tβ4) has been studied primarily for actin sequestration and cell migration. Actin is a structural protein critical to cell motility; Tβ4 binds monomeric actin (G-actin) and is implicated in cell migration during wound repair, particularly of endothelial and epithelial cells.
Research note: These are two different mechanisms studied in different model systems. Direct head-to-head comparative studies in the same injury model and species are rare in the published literature.
Why are they often discussed together?
Three reasons:
- Both have appeared in animal-model tissue-repair literature, so search results overlap.
- Both are commercially available from research-peptide suppliers in comparable lyophilized form factors.
- Some preclinical and observational research protocols evaluate the two in parallel to compare angiogenic vs. cell-migration effects.
Practical sourcing considerations
- Sequence verification. For TB-500 in particular, insist on a COA that specifies the exact peptide sequence supplied, since “TB-500” is a trade name rather than a strict chemical identifier.
- Purity. Both peptides are commonly supplied at ≥98% purity by HPLC. Lower purities can complicate interpretation of model results.
- Storage. Both should be kept lyophilized at −20°C and reconstituted shortly before use.
Further reading
For deeper background on either peptide individually, see our BPC-157 research guide and peptide storage guide. If you are evaluating a new vendor, our guide to reading a Certificate of Analysis is worth reviewing first.
Reminder: Information above summarizes preclinical research literature for laboratory and educational purposes only. It is not medical advice, and these compounds are not intended for human use.